Andere Sprachen Organon & Co.

Aktien

A3CPKP

US68622V1061

OGN

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 24.04.2024			% 5 Tage	% 1. Jan.
18.71 ^USD	+0.92%		+4.70%	+29.75%

09.04.	ORGANON & CO. : Morgan Stanley bekräftigt seine neutrale Bewertung	ZM
08.04.	Shanghai Henlius Biotech Denosumab Biosimilar HLX14 erreicht Endpunkt	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios	08.04.
L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires	08.04.
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	08.04.
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024	08.04.
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints	08.04.
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	20.03.
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health	08.03.
Philips : une nouvelle directrice financière en octobre	28.02.
New York attorney general urges stronger safety warning on asthma drug Singulair	23.02.
Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs, Replacing HUMIRA on Its National Formulary	21.02.
Organon's Hadlima Chosen by VA as Substitute for Humira	20.02.
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary	20.02.
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20.02.
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20.02.
Organon Launches U.S. Grant Programs and Listening Tour as Part of "Her Plan Is Her Power," Reaching High-Need Communities To Help Reduce Unplanned Pregnancies	20.02.
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	15.02.
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	15.02.
Organon: Q4 Earnings Snapshot	15.02.
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15.02.
Earnings Flash (OGN) ORGANON & CO. Posts Q4 Revenue $1.6B, vs. Street Est of $1.48B	15.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Organon & Co.

Aktien

A3CPKP

US68622V1061

OGN

Andere Sprachen

Filter